Incyte Net Worth
Incyte Net Worth Breakdown | INCY |
Incyte Net Worth Analysis
Incyte's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Incyte's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Incyte's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Incyte's net worth analysis. One common approach is to calculate Incyte's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Incyte's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Incyte's net worth. This approach calculates the present value of Incyte's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Incyte's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Incyte's net worth. This involves comparing Incyte's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Incyte's net worth relative to its peers.
Enterprise Value |
|
To determine if Incyte is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Incyte's net worth research are outlined below:
| Incyte generated a negative expected return over the last 90 days | |
| Incyte has a strong financial position based on the latest SEC filings | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Nisa Investment Advisors LLC Has 1.56 Million Stock Position in Incyte Co. - MarketBeat |
Incyte uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Incyte. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Incyte's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Incyte Target Price Consensus
Incyte target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Incyte's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 27 | Buy |
Most Incyte analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Incyte stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Incyte, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIncyte Target Price Projection
Incyte's current and average target prices are 73.72 and 79.42, respectively. The current price of Incyte is the price at which Incyte is currently trading. On the other hand, Incyte's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Incyte Target Price
Know Incyte's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Incyte is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Incyte backward and forwards among themselves. Incyte's institutional investor refers to the entity that pools money to purchase Incyte's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-09-30 | 2.2 M | Bellevue Group Ag | 2024-09-30 | 2.2 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 2.1 M | Norges Bank | 2024-06-30 | 2.1 M | Mizuho Securities Usa Inc | 2024-09-30 | 2 M | Legal & General Group Plc | 2024-09-30 | 1.7 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.6 M | Northern Trust Corp | 2024-09-30 | 1.5 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 1.4 M | Baker Bros Advisors Lp | 2024-09-30 | 30.7 M | Vanguard Group Inc | 2024-09-30 | 20.4 M |
Follow Incyte's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 14.2 B.Market Cap |
|
Project Incyte's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.08 | 0.09 | |
| Return On Capital Employed | 0.10 | 0.11 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | 0.10 | 0.19 |
When accessing Incyte's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Incyte's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Incyte's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Incyte's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Incyte. Check Incyte's Beneish M Score to see the likelihood of Incyte's management manipulating its earnings.
Evaluate Incyte's management efficiency
Return On Tangible Assets is likely to rise to 0.09 in 2025. Return On Capital Employed is likely to rise to 0.11 in 2025. At this time, Incyte's Return On Assets are fairly stable compared to the past year. Incyte's management efficiency ratios could be used to measure how well Incyte manages its routine affairs as well as how well it operates its assets and liabilities.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 20.89 | 21.93 | |
| Tangible Book Value Per Share | 19.76 | 20.75 | |
| Enterprise Value Over EBITDA | 10.64 | 11.17 | |
| Price Book Value Ratio | 3.11 | 3.27 | |
| Enterprise Value Multiple | 10.64 | 11.17 | |
| Price Fair Value | 3.11 | 3.27 | |
| Enterprise Value | 12.7 B | 13.4 B |
Incyte showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 3.058 | Revenue | Quarterly Revenue Growth 0.238 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Incyte insiders, such as employees or executives, is commonly permitted as long as it does not rely on Incyte's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Incyte insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Incyte Corporate Filings
F4 | 22nd of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 10th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 8th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
13A | 21st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Incyte Earnings Estimation Breakdown
The calculation of Incyte's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Incyte is estimated to be 0.328625 with the future projection ranging from a low of 0.2625 to a high of 0.4125. Please be aware that this consensus of annual earnings estimates for Incyte is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.26 Lowest | Expected EPS | 0.41 Highest |
Incyte Earnings Projection Consensus
Suppose the current estimates of Incyte's value are higher than the current market price of the Incyte stock. In this case, investors may conclude that Incyte is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Incyte's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 27 | 76.44% | 1.07 | 0.328625 | 0.09 |
Incyte Earnings per Share Projection vs Actual
Actual Earning per Share of Incyte refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Incyte predict the company's earnings will be in the future. The higher the earnings per share of Incyte, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Incyte Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Incyte, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Incyte should always be considered in relation to other companies to make a more educated investment decision.Incyte Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Incyte's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-29 | 2024-09-30 | 1.07 | 1.07 | 0.0 | 0 | ||
2024-07-30 | 2024-06-30 | -1.55 | -1.82 | -0.27 | 17 | ||
2024-04-30 | 2024-03-31 | 0.84 | 0.64 | -0.2 | 23 | ||
2024-02-13 | 2023-12-31 | 1.16 | 1.06 | -0.1 | 8 | ||
2023-10-31 | 2023-09-30 | 1.02 | 1.1 | 0.08 | 7 | ||
2023-08-01 | 2023-06-30 | 0.83 | 0.99 | 0.16 | 19 | ||
2023-05-02 | 2023-03-31 | 0.76 | 0.37 | -0.39 | 51 | ||
2023-02-07 | 2022-12-31 | 0.58 | 0.62 | 0.04 | 6 | ||
2022-11-01 | 2022-09-30 | 0.72 | 0.6 | -0.12 | 16 | ||
2022-08-02 | 2022-06-30 | 0.76 | 1.01 | 0.25 | 32 | ||
2022-05-03 | 2022-03-31 | 0.67 | 0.55 | -0.12 | 17 | ||
2022-02-08 | 2021-12-31 | 0.87 | 0.1 | -0.77 | 88 | ||
2021-11-02 | 2021-09-30 | 0.75 | 1.18 | 0.43 | 57 | ||
2021-08-03 | 2021-06-30 | 0.74 | 0.8 | 0.06 | 8 | ||
2021-05-04 | 2021-03-31 | 0.64 | 0.67 | 0.03 | 4 | ||
2021-02-09 | 2020-12-31 | 0.75 | 0.93 | 0.18 | 24 | ||
2020-11-05 | 2020-09-30 | 0.75 | 0.23 | -0.52 | 69 | ||
2020-08-04 | 2020-06-30 | 0.87 | 1.24 | 0.37 | 42 | ||
2020-05-05 | 2020-03-31 | 0.61 | -2.86 | -3.47 | 568 | ||
2020-02-13 | 2019-12-31 | 0.57 | 0.65 | 0.08 | 14 | ||
2019-10-29 | 2019-09-30 | 0.65 | 0.82 | 0.17 | 26 | ||
2019-07-30 | 2019-06-30 | 0.48 | 0.75 | 0.27 | 56 | ||
2019-04-30 | 2019-03-31 | 0.4 | 0.62 | 0.22 | 55 | ||
2019-02-14 | 2018-12-31 | 0.46 | 0.4 | -0.06 | 13 | ||
2018-10-30 | 2018-09-30 | 0.4 | 0.38 | -0.02 | 5 | ||
2018-07-31 | 2018-06-30 | 0.34 | 0.26 | -0.08 | 23 | ||
2018-05-01 | 2018-03-31 | 0.04 | -0.01 | -0.05 | 125 | ||
2018-02-15 | 2017-12-31 | -0.45 | -0.71 | -0.26 | 57 | ||
2017-10-31 | 2017-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2017-08-01 | 2017-06-30 | -0.05 | -0.06 | -0.01 | 20 | ||
2017-05-04 | 2017-03-31 | -1 | -0.68 | 0.32 | 32 | ||
2017-02-14 | 2016-12-31 | 0.13 | 0.05 | -0.08 | 61 | ||
2016-11-01 | 2016-09-30 | -0.01 | 0.19 | 0.2 | 2000 | ||
2016-08-09 | 2016-06-30 | -0.02 | 0.19 | 0.21 | 1050 | ||
2016-05-09 | 2016-03-31 | 0.17 | 0.12 | -0.05 | 29 | ||
2016-02-11 | 2015-12-31 | 0.09 | 0.29 | 0.2 | 222 | ||
2015-11-03 | 2015-09-30 | -0.41 | -0.22 | 0.19 | 46 | ||
2015-08-04 | 2015-06-30 | -0.11 | -0.09 | 0.02 | 18 | ||
2015-04-30 | 2015-03-31 | -0.1 | -0.11 | -0.01 | 10 | ||
2015-02-12 | 2014-12-31 | -0.09 | -0.22 | -0.13 | 144 | ||
2014-10-30 | 2014-09-30 | 0.01 | 0.33 | 0.32 | 3200 | ||
2014-07-31 | 2014-06-30 | -0.04 | -0.22 | -0.18 | 450 | ||
2014-05-01 | 2014-03-31 | -0.18 | -0.21 | -0.03 | 16 | ||
2014-02-12 | 2013-12-31 | -0.11 | -0.15 | -0.04 | 36 | ||
2013-10-31 | 2013-09-30 | -0.13 | -0.14 | -0.01 | 7 | ||
2013-08-01 | 2013-06-30 | 0.08 | 0.05 | -0.03 | 37 | ||
2013-05-02 | 2013-03-31 | -0.19 | -0.12 | 0.07 | 36 | ||
2013-02-14 | 2012-12-31 | -0.02 | 0.14 | 0.16 | 800 | ||
2012-11-01 | 2012-09-30 | -0.21 | -0.17 | 0.04 | 19 | ||
2012-04-26 | 2012-03-31 | -0.46 | -0.36 | 0.1 | 21 | ||
2012-02-15 | 2011-12-31 | -0.39 | -0.44 | -0.05 | 12 | ||
2011-10-27 | 2011-09-30 | -0.45 | -0.42 | 0.03 | 6 | ||
2011-07-28 | 2011-06-30 | -0.36 | -0.41 | -0.05 | 13 | ||
2011-05-03 | 2011-03-31 | -0.32 | -0.21 | 0.11 | 34 | ||
2011-02-10 | 2010-12-31 | 0.19 | 0.24 | 0.05 | 26 | ||
2010-11-09 | 2010-09-30 | -0.32 | -0.26 | 0.06 | 18 | ||
2010-08-05 | 2010-06-30 | -0.04 | 0.02 | 0.06 | 150 | ||
2010-05-06 | 2010-03-31 | -0.32 | -0.3 | 0.02 | 6 | ||
2010-02-18 | 2009-12-31 | -0.36 | -0.41 | -0.05 | 13 | ||
2009-11-05 | 2009-09-30 | -0.4 | -0.44 | -0.04 | 10 | ||
2009-07-30 | 2009-06-30 | -0.41 | -0.41 | 0.0 | 0 | ||
2009-05-07 | 2009-03-31 | -0.41 | -0.41 | 0.0 | 0 | ||
2009-02-18 | 2008-12-31 | -0.48 | -0.5 | -0.02 | 4 | ||
2008-11-06 | 2008-09-30 | -0.5 | -0.48 | 0.02 | 4 | ||
2008-07-29 | 2008-06-30 | -0.5 | -0.54 | -0.04 | 8 | ||
2008-04-30 | 2008-03-31 | -0.47 | -0.47 | 0.0 | 0 | ||
2008-02-14 | 2007-12-31 | -0.28 | -0.26 | 0.02 | 7 | ||
2007-11-01 | 2007-09-30 | -0.27 | -0.29 | -0.02 | 7 | ||
2007-07-26 | 2007-06-30 | -0.27 | -0.22 | 0.05 | 18 | ||
2007-05-03 | 2007-03-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2007-02-15 | 2006-12-31 | -0.25 | -0.24 | 0.01 | 4 | ||
2006-11-02 | 2006-09-30 | -0.24 | -0.19 | 0.05 | 20 | ||
2006-07-27 | 2006-06-30 | -0.24 | -0.24 | 0.0 | 0 | ||
2006-05-04 | 2006-03-31 | -0.26 | -0.21 | 0.05 | 19 | ||
2006-02-16 | 2005-12-31 | -0.31 | -0.33 | -0.02 | 6 | ||
2005-11-01 | 2005-09-30 | -0.38 | -0.36 | 0.02 | 5 | ||
2005-08-01 | 2005-06-30 | -0.33 | -0.3 | 0.03 | 9 | ||
2005-05-04 | 2005-03-31 | -0.33 | -0.24 | 0.09 | 27 | ||
2005-02-28 | 2004-12-31 | -0.35 | -0.47 | -0.12 | 34 | ||
2004-11-04 | 2004-09-30 | -0.43 | -0.35 | 0.08 | 18 | ||
2004-08-04 | 2004-06-30 | -0.4 | -0.87 | -0.47 | 117 | ||
2004-05-04 | 2004-03-31 | -0.45 | -0.52 | -0.07 | 15 | ||
2004-02-02 | 2003-12-31 | -0.49 | -0.56 | -0.07 | 14 | ||
2003-11-04 | 2003-09-30 | -0.39 | -0.6 | -0.21 | 53 | ||
2003-07-30 | 2003-06-30 | -0.39 | -0.37 | 0.02 | 5 | ||
2003-05-05 | 2003-03-31 | -0.28 | -0.36 | -0.08 | 28 | ||
2003-02-19 | 2002-12-31 | -0.39 | -0.45 | -0.06 | 15 | ||
2002-11-12 | 2002-09-30 | -0.37 | -0.45 | -0.08 | 21 | ||
2002-07-25 | 2002-06-30 | -0.28 | -0.26 | 0.02 | 7 | ||
2002-05-01 | 2002-03-31 | -0.21 | -0.2 | 0.01 | 4 | ||
2002-02-13 | 2001-12-31 | -0.76 | -0.22 | 0.54 | 71 | ||
2001-10-25 | 2001-09-30 | -0.19 | -0.27 | -0.08 | 42 | ||
2001-07-19 | 2001-06-30 | -0.23 | -0.15 | 0.08 | 34 | ||
2001-04-25 | 2001-03-31 | -0.28 | -0.16 | 0.12 | 42 | ||
2001-02-01 | 2000-12-31 | -0.12 | -0.11 | 0.01 | 8 | ||
2000-10-17 | 2000-09-30 | -0.12 | -0.12 | 0.0 | 0 | ||
2000-07-18 | 2000-06-30 | -0.22 | -0.1 | 0.12 | 54 | ||
2000-04-19 | 2000-03-31 | -0.28 | -0.13 | 0.15 | 53 | ||
2000-01-26 | 1999-12-31 | -0.12 | -0.11 | 0.01 | 8 | ||
1999-10-19 | 1999-09-30 | -0.19 | -0.19 | 0.0 | 0 | ||
1999-07-14 | 1999-06-30 | -0.11 | -0.11 | 0.0 | 0 | ||
1999-04-21 | 1999-03-31 | -0.08 | -0.04 | 0.04 | 50 | ||
1999-02-03 | 1998-12-31 | 0.1 | 0.12 | 0.02 | 20 | ||
1998-10-14 | 1998-09-30 | 0.1 | 0.08 | -0.02 | 20 | ||
1998-07-14 | 1998-06-30 | 0.09 | 0.1 | 0.01 | 11 | ||
1998-04-08 | 1998-03-31 | 0.08 | 0.08 | 0.0 | 0 | ||
1998-01-13 | 1997-12-31 | 0.07 | 0.09 | 0.02 | 28 | ||
1997-10-15 | 1997-09-30 | 0.06 | 0.06 | 0.0 | 0 | ||
1997-07-15 | 1997-06-30 | 0.04 | 0.04 | 0.0 | 0 | ||
1997-04-17 | 1997-03-31 | 0.03 | 0.02 | -0.01 | 33 | ||
1997-02-26 | 1996-12-31 | 0.01 | 0.01 | 0.0 | 0 | ||
null | null | null | null | null | 0 | ||
1996-07-25 | 1996-06-30 | -0.03 | -0.04 | -0.01 | 33 | ||
1996-04-25 | 1996-03-31 | -0.04 | -0.04 | 0.0 | 0 | ||
1996-02-21 | 1995-12-31 | -0.06 | -0.06 | 0.0 | 0 | ||
1995-10-25 | 1995-09-30 | -0.06 | -0.09 | -0.03 | 50 |
Incyte Corporate Management
| Sheila JD | General VP | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Paula Swain | Executive Resources | Profile | |
| Christine Chiou | Head Relations | Profile | |
| Michael Morrissey | Executive Operations | Profile | |
| PharmD MBA | Executive America | Profile |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.